Literature DB >> 1585469

The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients.

P R Chocair1, J A Duley, H A Simmonds, J S Cameron.   

Abstract

The immunosuppressive efficacy of azathioprine is related to its rapid metabolism in vivo to 6-mercaptopurine (6MP), with subsequent conversion to thioguanine nucleotides by an anabolic route involving hypoxanthine-guanine phosphoribosyltransferase. Two alternative catabolic routes exist: oxidation to 6-thiouric acid via xanthine oxidase and methylation to 6-methylmercaptopurine via the enzyme thiopurine methyltransferase (TPMT). Catabolism via either route would restrict formation of the active metabolites. We analyzed TPMT activity in erythrocyte lysates of 25 controls, 25 uremic patients on dialysis, and 68 transplanted patients. Median activity was lower in controls (31.0 pmol/hr/mg Hb, range 16.2-43.0) and transplanted patients receiving only cyclosporine and prednisolone (31.7 pmol/hr/mg Hb, range 12.7-43.5) than in the azathioprine treated group, (36.1 pmol/hr/mg Hb, range 16.1-71.3), or the uremic group on dialysis, (35.5 pmol/hr/mg Hb, range 18.6-62.6) suggesting that both azathioprine and uremia induce the enzyme, but CsA does not. Only 3 patients demonstrated total intolerance to azathioprine, 2 of whom had very low TPMT activity (zero and 12.7 pmol/hr/mg Hb). The intolerance of the third patient, despite high TPMT activity, was attributed to concomitant cotrimoxazole therapy. Patients with intermediate activity (15-26 pmol/hr/mg Hb) could tolerate azathioprine well. Of 29 cadaver recipients given only azathioprine plus prednisolone, 24 with a better clinical outcome had a significantly lower activity (33.1 pmol/hr/mg Hb, range 16.1-46.1) than 5 with reduced allograft function (42.5 pmol/hr/mg Hb, range 33.8-51.5). TPMT activity in these 24 patients was also significantly lower than the general group of azathioprine-treated recipients. This inverse association between TPMT activity and allograft function was again found among 30 patients receiving triple therapy (azathioprine, CsA, prednisolone). Self-selection of the best recipients for azathioprine immunosuppression apparently occurred, based on low catabolism of the drug. We conclude that total intolerance to azathioprine is rare and usually appears in patients with very low TPMT activities. Our results also suggest that the wide range of TPMT activity may be an important factor in determining long-term graft survival in azathioprine-treated patients; those with high activity might benefit from doses near the upper limit generally recommended.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1585469     DOI: 10.1097/00007890-199205000-00016

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  21 in total

Review 1.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine.

Authors:  T Dervieux; Y Médard; V Baudouin; A Maisin; D Zhang; F Broly; C Loirat; E Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

Review 3.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Pharmacogenetics of cancer therapy: getting personal.

Authors:  E Y Krynetski; W E Evans
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

Review 5.  When to investigate for purine and pyrimidine disorders. Introduction and review of clinical and laboratory indications.

Authors:  H A Simmonds; J A Duley; L D Fairbanks; M B McBride
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

Review 6.  Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.

Authors:  María del Mar Fernández De Gatta; Dolores Santos-Buelga; Alfonso Domínguez-Gil; María José García
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.

Authors:  E Y Krynetski; W E Evans
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

8.  Thiopurine S-methyltransferase as a target for drug interactions.

Authors:  Hua-Wen Xin; Christine Fischer; Matthias Schwab; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2005-06-11       Impact factor: 2.953

Review 9.  When and how does one search for inborn errors of purine and pyrimidine metabolism?

Authors:  H A Simmonds
Journal:  Pharm World Sci       Date:  1994-04-15

10.  Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.

Authors:  W R Connell; M A Kamm; J K Ritchie; J E Lennard-Jones
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.